ClinicalTrials.gov
public full text
Public Domain
5-Year Safety Study of Pimecrolimus Cream 1% in Infants 3 - 12 Months of Age With Mild to Moderate Atopic Dermatitis
The primary purpose of this study is to investigate the safety of pimecrolimus cream 1% in the long-term treatment (up to 5 years) of atopic dermatitis (eczema) in patients less than 12 months of age compared to topical corticosteroids (TCS).
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Pimecrolimus Cream 1% Plus Topical Corticosteroid in Patients (2-17 Years of Age) With Severe Atopic Dermatitis#841808
- Safety and Efficacy of CD5024 0.3% Cream in Subjects With Atopic Dermatitis#834174
- Evaluating the Effect of Bathing Additives in Atopic Dermatitis#1138722
- Paediatric atopic eczema (atopic dermatitis) in South Africa : a practical algorithm for the management of mild-to-moderate disease in daily clinical practice#637727
- Impact of the Daily Use of Emollient on Corticosteroids Consumption in Patients With Atopic Dermatitis#1124508
Record · ID 1384673
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive